Eventide Asset Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Eventide Asset Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-728,385	Closed	-$18M	–	153
2022 Q2	$18M	Hold	728,385	–	–	0.39%	74
2022 Q1	$18.3M	Sell	728,385 -311,615	-30%	-$8.76M	0.29%	89
2021 Q4	$37.9M	Hold	1,040,000	–	–	0.48%	69
2021 Q3	$17.8M	Sell	1,040,000 -363,000	-26%	-$5.66M	0.23%	102
2021 Q2	$18.8M	Buy	1,403,000 +843,000	+151%	+$20.8M	0.25%	96
2021 Q1	$28.7M	Buy	560,000 +173,000	+45%	+$10.4M	0.43%	76
2020 Q4	$24M	Buy	387,000 +90,000	+30%	+$5.15M	0.37%	82
2020 Q3	$16.3M	Buy	297,000 +122,000	+70%	+$6.57M	0.32%	86
2020 Q2	$10.1M	Buy	+175,000	New	+$9.52M	0.22%	94

Other funds holding CCXI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Eventide Asset Management's CCXI Position: Q3 2022 in Review

Eventide Asset Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2022, closing a stake of 728,385 shares — an estimated $18M sold.

Eventide Asset Management first reported a position in CCXI in Q2 2020 and held it in 9 quarters. The position peaked at $37.9M in Q4 2021. 217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

Eventide Asset Management reported no remaining ChemoCentryx, Inc. position as of Q3 2022 after selling out during the quarter.
Eventide Asset Management sold 728,385 ChemoCentryx, Inc. shares in Q3 2022, an estimated $18M.
Eventide Asset Management first reported a position in ChemoCentryx, Inc. in Q2 2020 and held it in 9 quarters.
Eventide Asset Management's ChemoCentryx, Inc. position peaked at $37.9M in Q4 2021.
217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on Eventide Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.